1
|
Ziani PR, de Bastiani MA, Alves PP, da Rosa PH, Schons T, Mezzomo G, Scotton E, Kapczinski F, Rosa AR. Proteomic Insights into Biology of Bipolar Disorder: Implications for Health Complexity and Mortality. Trends Psychiatry Psychother 2024. [PMID: 38687951 DOI: 10.47626/2237-6089-2024-0820] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 02/15/2024] [Accepted: 04/23/2024] [Indexed: 05/02/2024]
Abstract
OBJECTIVE The present study has the following objectives: 1) identify differentially expressed proteins and pathways in blood samples of BD compared to healthy controls by employing high-throughput proteomics and bioinformatics and 2) characterize disease-related molecular signatures through in-depth analysis of the differentially expressed proteins and pathways. METHODS Blood samples from BD patients (n=10) classified into high (BD+) or poor functioning (BD-), based on functional and cognitive status, and healthy controls (n=5) were analyzed using mass spectrometry-based proteomic analysis. Bioinformatics was performed to detect biological processes, pathways, and diseases related to BD. RESULTS Eight proteins exclusively characterized the molecular profile of patients with BD+ compared to HC, while 26 altered proteins were observed in the BD- group. These altered proteins were mainly enriched in biological processes related to lipid metabolism, complement system and coagulation cascade, and cardiovascular diseases; all these changes were more prominent in the BD- group. CONCLUSION These findings may represent systemic alterations that occur with the progression of the illness and a possible link between BD and medical comorbidities. Such comprehensive understanding provides valuable insights for targeted interventions, addressing mental and physical health aspects in subjects with BD. Despite these promising findings, further research is warranted, encompassing larger sample cohorts and incorporating biological validation through molecular biology methods.
Collapse
Affiliation(s)
- Paola Rampelotto Ziani
- Laboratory of Molecular Psychiatry, Hospital Clinic of Porto Alegre (HCPA), Porto Alegre, RS, Brazil. Department of Pharmacology and Graduate Program of Pharmacology and Therapeutics, Institute for Basic Medical Science, University Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil
| | - Marco Antônio de Bastiani
- Department of Pharmacology and Graduate Program of Pharmacology and Therapeutics, Institute for Basic Medical Science, University Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil
| | - Pietra Paiva Alves
- Laboratory of Molecular Psychiatry, Hospital Clinic of Porto Alegre (HCPA), Porto Alegre, RS, Brazil
| | - Pedro Henrique da Rosa
- Laboratory of Molecular Psychiatry, Hospital Clinic of Porto Alegre (HCPA), Porto Alegre, RS, Brazil. Department of Pharmacology and Graduate Program of Pharmacology and Therapeutics, Institute for Basic Medical Science, University Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil
| | - Tainá Schons
- Laboratory of Molecular Psychiatry, Hospital Clinic of Porto Alegre (HCPA), Porto Alegre, RS, Brazil
| | - Giovana Mezzomo
- Laboratory of Molecular Psychiatry, Hospital Clinic of Porto Alegre (HCPA), Porto Alegre, RS, Brazil. Department of Pharmacology and Graduate Program of Pharmacology and Therapeutics, Institute for Basic Medical Science, University Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil
| | - Ellen Scotton
- Laboratory of Molecular Psychiatry, Hospital Clinic of Porto Alegre (HCPA), Porto Alegre, RS, Brazil. Department of Pharmacology and Graduate Program of Pharmacology and Therapeutics, Institute for Basic Medical Science, University Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil
| | - Flávio Kapczinski
- Laboratory of Molecular Psychiatry, Hospital Clinic of Porto Alegre (HCPA), Porto Alegre, RS, Brazil. Department of Pharmacology and Graduate Program of Pharmacology and Therapeutics, Institute for Basic Medical Science, University Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil. Graduate Program in Psychiatry and Behavioral Sciences, School of Medicine, University Federal of Rio Grande do Sul, Porto Alegre, RS, Brazil
| | - Adriane R Rosa
- Laboratory of Molecular Psychiatry, Hospital Clinic of Porto Alegre (HCPA), Porto Alegre, RS, Brazil. Department of Pharmacology and Graduate Program of Pharmacology and Therapeutics, Institute for Basic Medical Science, University Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil. Graduate Program in Psychiatry and Behavioral Sciences, School of Medicine, University Federal of Rio Grande do Sul, Porto Alegre, RS, Brazil
| |
Collapse
|
2
|
Ziani PR, de Bastiani MA, Scotton E, da Rosa PH, Schons T, Mezzomo G, de Carvalho Q, Kapczinski F, Rosa AR. Drug Repurposing and Personalized Treatment Strategies for Bipolar Disorder Using Transcriptomic. Braz J Psychiatry 2024. [PMID: 38446713 DOI: 10.47626/1516-4446-2023-3441] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/16/2023] [Accepted: 01/10/2024] [Indexed: 03/08/2024]
Abstract
OBJECTIVE The present study combined transcriptomic data and computational techniques based on gene expression signatures to identify novel bioactive compounds or FDA-approved drugs for the management of Bipolar Disorder (BD). METHODS Five transcriptomic datasets, comprising a total of 165 blood samples from BD case-control, were selected from the Gene Expression Omnibus repository (GEO). The number of subjects varied from 6 to 60, with a mean age ranging from 35 to 48, with a gender variation between them. Most of the patients were on pharmacological treatment. Master Regulator Analysis (MRA) and Gene Set Enrichment Analysis (GSEA) were performed to identify statistically significant genes between BD and HC and their association with the mood states of BD. Additionally, existing molecules with the potential to reverse the transcriptomic profiles of disease-altered regulons in BD were identified using the LINCS and cMap databases. RESULTS MRA identified 59 potential MRs candidates modulating the regulatory units enriched with genes altered in BD, while the GSEA identified 134 enriched genes, and a total of 982 regulons had their activation state determined. Both analyses showed genes exclusively associated with mania, depression, or euthymia, and some genes were common between the three mood states. We identified bioactive compounds and licensed drug candidates, including antihypertensives and antineoplastics, as promising candidates for treating BD. Nevertheless, experimental validation is essential to authenticate these findings in subsequent studies. CONCLUSION Although preliminary, our data provides some insights regarding the biological patterns of BD into distinct mood states and potential therapeutic targets. The combined transcriptomic and bioinformatics strategy offers a route to advance drug discovery and personalized medicine by tapping into gene expression information.
Collapse
Affiliation(s)
- Paola Rampelotto Ziani
- Laboratory of Molecular Psychiatry, Hospital Clinic of Porto Alegre, Porto Alegre, Brazil. Postgraduate Program in Biological Sciences: Pharmacology and Therapeutics - Institute of Basic Health Sciences, University Federal of Rio Grande do Sul, Porto Alegre, RS, Brazil
| | - Marco Antônio de Bastiani
- Postgraduate Program in Biological Sciences: Pharmacology and Therapeutics - Institute of Basic Health Sciences, University Federal of Rio Grande do Sul, Porto Alegre, RS, Brazil
| | - Ellen Scotton
- Laboratory of Molecular Psychiatry, Hospital Clinic of Porto Alegre, Porto Alegre, Brazil. Postgraduate Program in Biological Sciences: Pharmacology and Therapeutics - Institute of Basic Health Sciences, University Federal of Rio Grande do Sul, Porto Alegre, RS, Brazil
| | - Pedro Henrique da Rosa
- Laboratory of Molecular Psychiatry, Hospital Clinic of Porto Alegre, Porto Alegre, Brazil. Postgraduate Program in Biological Sciences: Pharmacology and Therapeutics - Institute of Basic Health Sciences, University Federal of Rio Grande do Sul, Porto Alegre, RS, Brazil
| | - Tainá Schons
- Laboratory of Molecular Psychiatry, Hospital Clinic of Porto Alegre, Porto Alegre, Brazil
| | - Giovana Mezzomo
- Laboratory of Molecular Psychiatry, Hospital Clinic of Porto Alegre, Porto Alegre, Brazil. Postgraduate Program in Biological Sciences: Pharmacology and Therapeutics - Institute of Basic Health Sciences, University Federal of Rio Grande do Sul, Porto Alegre, RS, Brazil
| | - Quênia de Carvalho
- Laboratory of Molecular Psychiatry, Hospital Clinic of Porto Alegre, Porto Alegre, Brazil. Postgraduate Program in Biological Sciences: Pharmacology and Therapeutics - Institute of Basic Health Sciences, University Federal of Rio Grande do Sul, Porto Alegre, RS, Brazil
| | - Flávio Kapczinski
- Laboratory of Molecular Psychiatry, Hospital Clinic of Porto Alegre, Porto Alegre, Brazil. Department of Psychiatry, University Federal of Rio Grande do Sul, Porto Alegre, RS, Brazil. National Institute of Translational Science and Technology in Medicine, Porto Alegre, RS, Brazil. Department of Psychiatry and Behavioral Neurosciences, McMaster University, Hamilton, ON, Canada
| | - Adriane R Rosa
- Laboratory of Molecular Psychiatry, Hospital Clinic of Porto Alegre, Porto Alegre, Brazil. Postgraduate Program in Biological Sciences: Pharmacology and Therapeutics - Institute of Basic Health Sciences, University Federal of Rio Grande do Sul, Porto Alegre, RS, Brazil. Department of Pharmacology, Institute of Basic Science Health, University Federal of Rio Grande do Sul, Porto Alegre, RS, Brazil
| |
Collapse
|
3
|
Ziani PR, Feiten JG, Goularte JF, Colombo R, Antqueviezc B, Géa LP, Rosa AR. Potential Candidates for Biomarkers in Bipolar Disorder: A Proteomic Approach through Systems Biology. Clin Psychopharmacol Neurosci 2022; 20:211-227. [PMID: 35466093 PMCID: PMC9048014 DOI: 10.9758/cpn.2022.20.2.211] [Citation(s) in RCA: 6] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 05/20/2021] [Revised: 07/02/2021] [Accepted: 07/03/2021] [Indexed: 11/18/2022]
Affiliation(s)
- Paola Rampelotto Ziani
- Laboratory of Molecular Psychiatry, Hospital Clinic of Porto Alegre, Porto Alegre, Brasil
- Postgraduate Program in Biological Sciences: Pharmacology and Therapeutics - Institute of Basic Health Sciences, Federal University of Rio Grande do Sul, Porto Alegre, Brasil
| | - Jacson Gabriel Feiten
- Laboratory of Molecular Psychiatry, Hospital Clinic of Porto Alegre, Porto Alegre, Brasil
- Postgraduate Program in Psychiatry and Behavioral Sciences, Faculty of Medicine, Federal University of Rio Grande do Sul, Porto Alegre, Brasil
| | | | - Rafael Colombo
- Laboratory of Molecular Psychiatry, Hospital Clinic of Porto Alegre, Porto Alegre, Brasil
- University of Caxias do Sul, Caxias do Sul, Brasil
| | - Bárbara Antqueviezc
- Laboratory of Molecular Psychiatry, Hospital Clinic of Porto Alegre, Porto Alegre, Brasil
| | - Luiza Paul Géa
- Department of Psychiatry and Behavioural Neurosciences, McMaster University, Hamilton, ON, Canada
| | - Adriane Ribeiro Rosa
- Laboratory of Molecular Psychiatry, Hospital Clinic of Porto Alegre, Porto Alegre, Brasil
- Postgraduate Program in Biological Sciences: Pharmacology and Therapeutics - Institute of Basic Health Sciences, Federal University of Rio Grande do Sul, Porto Alegre, Brasil
- Postgraduate Program in Psychiatry and Behavioral Sciences, Faculty of Medicine, Federal University of Rio Grande do Sul, Porto Alegre, Brasil
| |
Collapse
|